Off-Label Use of Malaria Drug Puts Patients at Risk for Blood Disorders, FDA Says

Published July 10, 2010

Off-Label Use of Malaria Drug Puts Patients at Risk For Blood Disorders, FDA Says
U.S. health regulators warned today that people who use the malaria drug Qualaquin to treat night time leg cramps face a serious risk of life-threatening blood disorders. AR Scientific, which distributes Qualaquin in the U.S., has developed a risk management plan aimed at educating health care professionals and patients about the potential risks. According to […]
Read more on NewsInferno

SurModics Showcases Drug Delivery Technology at The 37th Annual Meeting and Exposition of the Controlled Release Society
EDEN PRAIRIE, Minn.—-SurModics, Inc. , a leading provider of drug delivery and surface modification technologies to the healthcare industry, is participating at the 37th Annual Meeting and Exposition of the Controlled Release Society , July 10–14, 2010 in Portland, Oregon .
Read more on Business Wire via Yahoo! Finance

NICE Concerned Over Bone Cancer Drug’s Level Of Efficacy And High Cost In Draft Guidance
In evidence given to the National Institute for Health and Clinical Excellence (NICE), the drug, mifamurtide (Mepact, Takeda) has not been shown to significantly increase the overall survival of patients with a form of bone cancer more than currently available treatments…
Read more on Medical News Today